Medacta Group SA primarily develops, manufacture and distributes orthopedic and neurosurgical medical devices.
Business Segments
The company operates through a variety of segments focused on orthopedic products and services, particularly in areas…
Analysis
Hope premium
Medacta Group SA is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium. Worth noting: the cash the business generates has lagged behind what the income statement shows.
On valuation, the picture is expensive. The owner-earnings multiple stands at 97.1×; owner earnings: the cash an owner could take out each year.
Growth is moderate; the safety picture is adequate. The company scores 14/20 on our value-creation score: strong value creator.
Flags to be aware of: Some accounting patterns deserve a closer look. Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202335
41
2023202420252026
All-time high
87
Sep 2025
All-time low
35
Jan 2023
Average rank
65
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
15
15
16
31
Price/Earnings
18
21
21
44
Price/Book
14
6
1
14
Dividend Yield
40
33
49
42
Value (overall)
14
12
17
15
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.